Figure 1.
Internally Controlled Sensitivity Assays to Determine Effects of KIF2C or TACC3 Knockdown or Overexpression on Sensitivity to Rigosertibpharm, Rigosertibcomm, or ON01500
(A) CRISPRi drug sensitivity phenotypes for indicated sgRNAs.
(B) CRISPRa drug sensitivity phenotypes for indicated sgRNAs.
Enrichment is defined as ratio of sgRNA-positive cells to sgRNA-negative cells, normalized to the corresponding ratio after treatment with DMSO. n.d.: phenotype not determined because total counted cell numbers were < 2,500. Data represent mean and individual measurements of replicate treatments (n = 2).